Zacks Investment Research downgraded shares of LEMAITRE VASCLR (LMAT) from OUTPERFORM to NEUTRAL on May 30, 2013, with a target price of $6.90.
LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on LEMAITRE VASCLR (LMAT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment